Is STVN a good stock to buy right now?

Based on our 6-factor quantitative model, Stevanato Group S.p.A. (STVN) receives a "Reduce" rating with a composite score of 40.4/100. It is ranked #3,037 out of 4,446 stocks. Key factor scores: Quality 36/100, Value 67/100, Momentum 23/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for STVN?

Stevanato Group S.p.A. (STVN) has a "Reduce" rating and 2-star score. The composite score of 40.4 ranks it #3,037 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is STVN in?

Stevanato Group S.p.A. operates in the Healthcare sector (Medical Equipment industry) with a market cap of $3.75 billion. It is classified as a mid-cap stock.

Does STVN pay a dividend?

STVN does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is STVN's P/E ratio?

STVN has a trailing P/E ratio of 30.89x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is STVN?

STVN's quality factor score is 36/100. Gross margin: 27.4%. ROE: 33.5% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is STVN valued compared to peers?

STVN's value factor score is 67/100 (higher = cheaper). Key multiples: P/E 30.9x, EV/EBITDA 3.9x. The stock appears attractively valued versus peers.

What is STVN's debt level?

STVN's debt-to-equity ratio is 0%. Sector average: 32%. Low leverage suggests conservative financial management.

STVN has a beta of 1.04, meaning it tracks the market. Stability score: 41/100.

Does STVN have high short interest?

STVN's short interest factor score is 57/100 (higher = less short selling). Moderate short interest.

STVN Stock Analysis: Top Mid-Cap Reduce (Score 40.4/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
STVN	-1.67%	-1.53%	-10.29%	-32.80%	-34.46%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.61%	-5.13%	-10.62%	-32.44%	-63.99%	-	-	-
Alpha vs Sector	-0.32%	-1.87%	-6.47%	-27.96%	-43.67%	-	-	-

Metric	STVN	Benchmark
P/E Ratio	30.9x	+31%
EV/EBITDA	3.9x	-39%
Price / Book	2.6x	-7%

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
STVN Stevanato Group S.p.A.	40	36	67	23	30.9x	33.5%	27.4%	10.7%	-	0.0x	$3.8B

Key Ratio	TTM	2024	2023	2022	2021	2020
Gross Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%
FCF Margin %	-14.3%	-14.3%	-30.2%	-13.4%	30.9%	1.7%
ROE %	0.3%	0.1%	0.1%	0.2%	0.2%	0.3%
ROA %	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	9.7%	9.7%	14.9%	24.3%	43.2%	80.2%

Line Item	TTM	2024	2023	2022	2021	2020
	$1.1B	$1.1B	$1.2B	$1.1B	$955M	$827M
	$313M	$313M	$376M	$342M	$300M	$237M
Gross Margin	27.4%	27.4%	31.3%	32.5%	31.4%	29.3%
	—	$33M	$39M	$37M	$34M	$21M
Depreciation	—	$68M	$69M	$54M	$64M	$66M
	$167M	$167M	$222M	$206M	$184M	$144M
EBIT	$167M	$167M	$222M	$206M	$184M	$144M
EBITDA	$234M	$234M	$291M	$260M	$233M	$177M
Operating Margin	14.6%	14.6%	18.5%	19.6%	19.2%	15.6%
EBITDA Margin	20.5%	20.5%	24.3%	24.7%	24.3%	21.4%
	—	$24M	$35M	$32M	$21M	$27M
	—	$44M	$49M	$48M	$36M	$22M
	$122M	$122M	$161M	$153M	$152M	$96M
Net Margin	10.7%	10.7%	13.4%	14.5%	15.9%	11.9%
	$0.45	$0.45	$0.61	$0.58	$0.53	-
Diluted EPS	$0.45	$0.45	$0.61	$0.58	$0.53	-

Stevanato Group S.p.A. (STVN) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Stevanato Group S.p.A. Do?

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L. Stevanato Group S.p.A. (STVN) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Franco Moro and employs approximately 4,650 people. With a market capitalization of $3.8B, STVN is one of the notable companies in the Healthcare sector.

Stevanato Group S.p.A. (STVN) Stock Rating — Reduce (April 2026)

As of April 2026, Stevanato Group S.p.A. receives a Reduce rating with a composite score of 40.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.STVN ranks #3,037 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Stevanato Group S.p.A. ranks #443 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STVN Stock Price and 52-Week Range

Stevanato Group S.p.A. (STVN) currently trades at $13.52. The stock lost $0.23 (1.7%) in the most recent trading session. The 52-week high for STVN is $28.00, which means the stock is currently trading -51.7% from its annual peak. The 52-week low is $13.91, putting the stock -2.8% above its annual trough. Recent trading volume was 478K shares, suggesting relatively thin trading activity.

Is STVN Overvalued or Undervalued? — Valuation Analysis

Stevanato Group S.p.A. (STVN) carries a value factor score of 67/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 30.89x, compared to the Healthcare sector average of 23.63x — a premium of 31%. The price-to-book ratio stands at 2.56x, versus the sector average of 2.75x. The price-to-sales ratio is 0.81x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, STVN trades at 3.86x EV/EBITDA, versus 6.34x for the sector.

Overall, STVN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Stevanato Group S.p.A. Profitability — ROE, Margins, and Quality Score

Stevanato Group S.p.A. (STVN) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 33.5%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 20.2% versus the sector average of -33.1%.

On a margin basis, Stevanato Group S.p.A. reports gross margins of 27.4%, compared to 71.5% for the sector. The operating margin is 14.6% (sector: -66.1%). Net profit margin stands at 10.7%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STVN Debt, Balance Sheet, and Financial Health

Stevanato Group S.p.A. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $102M.

STVN has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Stevanato Group S.p.A. is 41/100, reflecting average volatility within the normal range for its sector.

Stevanato Group S.p.A. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Stevanato Group S.p.A. reported revenue of $1.14B and earnings per share (EPS) of $0.45. Net income for the quarter was $122M. Gross margin was 27.4%. Operating income came in at $167M.

In FY 2024, Stevanato Group S.p.A. reported revenue of $1.14B and earnings per share (EPS) of $0.45. Net income for the quarter was $122M. Gross margin was 27.4%. Revenue grew -4.8% year-over-year compared to FY 2023. Operating income came in at $167M.

In FY 2023, Stevanato Group S.p.A. reported revenue of $1.20B and earnings per share (EPS) of $0.61. Net income for the quarter was $161M. Gross margin was 31.3%. Revenue grew 14.1% year-over-year compared to FY 2022. Operating income came in at $222M.

In FY 2022, Stevanato Group S.p.A. reported revenue of $1.05B and earnings per share (EPS) of $0.58. Net income for the quarter was $153M. Gross margin was 32.5%. Revenue grew 10.2% year-over-year compared to FY 2021. Operating income came in at $206M.

Over the past 6 quarters, Stevanato Group S.p.A. has demonstrated a growth trajectory, with revenue expanding from $827M to $1.14B. Investors analyzing STVN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STVN Dividend Yield and Income Analysis

Stevanato Group S.p.A. (STVN) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STVN Momentum and Technical Analysis Profile

Stevanato Group S.p.A. (STVN) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 42/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

STVN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Stevanato Group S.p.A. (STVN) ranks #443 out of 838 stocks based on the Blank Capital composite score. This places STVN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STVN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STVN vs S&P 500 (SPY) comparison to assess how Stevanato Group S.p.A. stacks up against the broader market across all factor dimensions.

STVN Next Earnings Date

No upcoming earnings date has been announced for Stevanato Group S.p.A. (STVN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STVN? — Investment Thesis Summary

The quantitative profile for Stevanato Group S.p.A. suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 67/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 23/100, a headwind for near-term performance.

In summary, Stevanato Group S.p.A. (STVN) earns a Reduce rating with a composite score of 40.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STVN stock.

Related Resources for STVN Investors

Explore more research and tools: STVN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STVN head-to-head with peers: STVN vs AZN, STVN vs SLGL, STVN vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Stevanato Group’s (STVN) Core Business Improved Despite a 22% Pull Back in Q4

Here’s Why Artisan Small Cap Fund Remains Invested in Stevanato Group (STVN)

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group S.p.A. (NYSE:STVN) Q4 2025 Earnings Call Transcript

Stevanato Group outlines 2026 revenue target up to €1.308B with high-value solutions set to reach 48% of sales (NYSE:STVN)

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

Stevanato Group S.p.A. (STVN) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Stevanato Group S.p.A. Do?

Stevanato Group S.p.A. (STVN) Stock Rating — Reduce (April 2026)

STVN Stock Price and 52-Week Range

Is STVN Overvalued or Undervalued? — Valuation Analysis

Stevanato Group S.p.A. Profitability — ROE, Margins, and Quality Score

STVN Debt, Balance Sheet, and Financial Health

Stevanato Group S.p.A. Revenue and Earnings History — Quarterly Trend

STVN Dividend Yield and Income Analysis

STVN Momentum and Technical Analysis Profile

STVN vs Competitors — Healthcare Sector Ranking and Peer Comparison

STVN Next Earnings Date

Should You Buy STVN? — Investment Thesis Summary

Related Resources for STVN Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Gross Margin

Operating Margin

Executive Leadership

Corporate Intelligence

Net Margin

Return on Equity

Return on Assets

Debt/Equity

Audit Benchmarks

Insider Alignment Audit

Regulatory Disclosure Vault